How to Wean Off Inhaled Steroids Safely

Weaning off inhaled corticosteroids (ICS) is safest when done gradually, under medical guidance, and only after your symptoms have been well controlled for at least two to three months. The general approach is to cut your dose by about 25 to 50 percent at each step-down, wait several weeks to months, and confirm that your condition stays stable before reducing further. Rushing the process or stopping abruptly can trigger flare-ups, and in some cases, reveal a more serious problem: your adrenal glands may have grown dependent on the external steroid supply. The specifics vary quite a bit depending on whether you have asthma or COPD, how long you have been on inhaled steroids, and what dose you are taking.

Why Reducing Inhaled Steroids Is Worth Considering

Inhaled steroids are effective anti-inflammatory drugs, and for many people they are genuinely necessary. But they are not without cost, especially at higher doses or over long stretches. Local side effects like oral thrush are well known. What gets less attention is that inhaled steroids can also produce systemic effects: they can suppress the body’s natural cortisol production, reduce bone density, raise the risk of pneumonia, and affect the skin, eyes, and immune system.¹ The effect on bone mineral density and fracture risk appears to be dose-dependent, becoming most significant at high doses.²

A large study of people with COPD found that long-term inhaled steroid users had roughly triple the pneumonia rate and a meaningfully higher fracture rate compared to short-term users.³ These are not rare curiosities. That study translated its findings into a “number needed to harm” of just five, meaning for every five long-term users, one experienced a serious adverse event that a short-term user would not have. Numbers like that make the case for stepping down when your disease allows it.

When You Are a Candidate for Stepping Down

Not everyone on inhaled steroids should be looking to reduce. The right time depends on how stable your condition has been. For adults and adolescents with asthma, guidelines suggest considering a step-down when symptoms have been well controlled on a stable ICS dose for at least two to three months. For children, the recommendation is to wait longer, roughly six months, particularly if the current dose is medium or high.⁴ “Well controlled” here means you are not waking up at night with symptoms, you are not needing your rescue inhaler more than a couple of times a week, and your lung function is near your personal best.

Certain situations make stepping down riskier. If you have had a recent exacerbation, an upcoming respiratory infection season, or a known trigger you are about to be exposed to (like pollen season for someone with allergic asthma), your doctor will likely wait. The goal is to attempt the reduction during a calm window, not in the middle of instability.

How the Tapering Process Works

The standard method is to reduce your inhaled steroid dose by roughly 25 to 50 percent and then hold at that new dose for a period, usually at least three months, before considering another reduction. This stepwise approach gives your airways time to declare whether they still need the higher dose. When mild asthma is well controlled, cutting the dose in half is often tolerated. But more rapid tapering and more severe disease both predict a rougher ride.⁵

The honest reality is that stepping down does not always stick. About half of children and adults who stop inhaled steroids entirely will redevelop symptoms within a year.⁵ That does not mean the attempt was wasted. Even if you cannot come off entirely, you may be able to settle at a lower dose than where you started, which still reduces your exposure to side effects. Think of it as finding your minimum effective dose rather than aiming for zero.

If you are on a combination inhaler that includes both a steroid and a long-acting bronchodilator (a LABA), the typical approach is to reduce the steroid component first while keeping the bronchodilator in place. A randomized trial found that cutting the ICS dose while maintaining the LABA did not lead to a statistically significant increase in exacerbations compared to keeping the full combination stable.⁶ That said, the study could not definitively rule out a small difference, so monitoring during this process remains important.

The Adrenal Gland Problem

This is the part that makes abrupt stopping genuinely dangerous. Your adrenal glands produce cortisol, a hormone your body needs to handle physical stress: illness, injury, surgery, even severe emotional strain. When you take external steroids, even inhaled ones, your body can dial down its own cortisol production. If you then remove the external supply too quickly, your adrenals may not be able to ramp back up in time. The result is adrenal insufficiency, which in its acute form (adrenal crisis) can cause nausea, vomiting, dangerously low blood pressure, and low blood sugar.

This is not just a theoretical concern. Reviews have identified dozens of documented adrenal crises triggered by inhaled steroid use, and evidence of measurable adrenal suppression in hundreds of patients.⁷ Almost all the reported cases in children involved fluticasone doses of 500 micrograms per day or more.⁸ Higher-risk patients include those on high cumulative ICS doses, people who also take frequent courses of oral steroids, and those using medications that slow the liver’s breakdown of steroids (certain antifungals and HIV drugs, for instance).⁹

Adrenal suppression can persist for up to a year after you stop taking corticosteroids.⁸ If you have been on medium-to-high dose inhaled steroids for a long time, your doctor may check your cortisol levels before or during tapering. And during the tapering period, you should know the symptoms of adrenal insufficiency: persistent fatigue, dizziness, nausea, and muscle weakness. If you get seriously ill or need surgery while your adrenal function is still recovering, you may need a temporary “stress dose” of oral steroids to compensate.

Stepping Down With COPD Is a Different Conversation

In COPD, the evidence increasingly supports that many patients are on inhaled steroids who do not need them. Unlike asthma, where inflammation is almost always steroid-responsive, COPD inflammation is often driven by pathways that steroids do not help much. Large observational studies have found that stopping inhaled steroids in COPD patients with low exacerbation risk, while keeping them on adequate bronchodilator therapy, does not increase hospitalizations or severe flare-ups.¹⁰ In one study of over 11,000 COPD patients who stopped inhaled steroids for at least six months, 69 percent had no recorded exacerbation and 89 percent avoided hospitalization for COPD.¹⁰

The key variable is eosinophil count, a type of white blood cell measurable through a routine blood draw. When eosinophils are low, withdrawal tends to go smoothly. The WISDOM trial, which gradually tapered ICS over 12 weeks in COPD patients on triple therapy, found no increased exacerbation risk in the overall population. But patients with eosinophil counts above 300 cells per microliter did have a higher exacerbation risk when their inhaled steroid was removed.¹¹ A small Veterans Affairs study echoed this: of 75 COPD patients who discontinued ICS, only 7 percent had an exacerbation, and none of the nine patients whose ICS was tapered gradually (rather than stopped at once) experienced a flare-up.¹²

So if you have COPD, your doctor’s decision to attempt ICS withdrawal will lean heavily on two things: how often you have flare-ups and what your blood eosinophils look like. Patients with stable disease, infrequent exacerbations, and low eosinophils are the best candidates. Those with frequent exacerbations, high eosinophils, or a history of overlapping asthma features are generally better off staying on their steroid.¹¹

Blood Eosinophils and Exhaled Nitric Oxide as Guides

Two biomarkers are increasingly used to inform decisions about inhaled steroid tapering. Blood eosinophil count, already mentioned in the COPD context, is relevant in asthma as well. In COPD, eosinophil counts at or above 300 cells per microliter are associated with a higher risk of exacerbation generally and specifically with worse outcomes when steroids are withdrawn.¹³ One large real-world study found that even among patients with elevated eosinophils, ICS withdrawal did not increase the risk of moderate-to-severe exacerbations or death, though this finding has been debated.¹⁴ The weight of evidence still favors caution in high-eosinophil patients.

Fractional exhaled nitric oxide (FeNO) is a breath test that measures a gas produced by inflamed airways. It serves as a marker of the type of inflammation most responsive to steroids.¹⁵ A low FeNO reading suggests your airway inflammation is not particularly steroid-driven, which makes it more likely you can reduce your dose without trouble. A rising FeNO during tapering can serve as an early warning that inflammation is returning before you notice symptoms.¹⁶ Not every clinic has FeNO testing available, but if yours does, it can add a useful layer of safety to the tapering process.

Warning Signs That You Have Stepped Down Too Far

The most obvious sign is worsening symptoms: more coughing, chest tightness, nighttime awakenings, or increased rescue inhaler use. But symptoms sometimes lag behind the underlying inflammation. In one small steroid-withdrawal study, researchers found that measurable changes in airway inflammation, specifically a surge in certain inflammatory markers, showed up about two weeks before patients actually lost control of their asthma.¹⁷ You will not have sputum samples analyzed at home, of course. But the practical takeaway is that if you notice even mild worsening, do not write it off. It may be the beginning of a more significant slide. In that study, the majority of patients who had their steroids withdrawn lost control of their asthma within the ten-week observation period.¹⁷

If things do worsen, the plan should be straightforward: go back to the dose that was keeping you stable. Stepping down is not a one-way door. Your doctor should establish a clear action plan before you begin tapering, including how long to wait at each dose, what counts as loss of control, and what to do if that happens. Without that structure, patients tend to either push through worsening symptoms or panic and overshoot back to a higher dose than necessary.

Biologic Therapies as a Steroid-Sparing Strategy

For people with severe asthma who cannot taper their inhaled steroids without losing control, biologic therapies have changed the landscape. These are injectable medications that target specific immune pathways driving inflammation. In a study of patients with severe asthma using benralizumab (which targets eosinophils), 92 percent were able to reduce their inhaled steroid dose, and more than 60 percent stopped inhaled steroids entirely.¹⁸ Biologics are expensive and require regular injections, so they are not a first-line approach for mild disease. But for the subset of patients stuck on high-dose steroids because every attempt to reduce leads to flare-ups, biologics can be transformative, effectively removing the inflammation that the steroid was holding in check so the steroid is no longer needed.

Allergen Immunotherapy and Steroid Reduction

If your asthma is driven by a specific allergy, such as house dust mites, addressing the root trigger through allergen immunotherapy may reduce your need for inhaled steroids over time. In a randomized trial of children with dust-mite-allergic asthma, those receiving allergen injections alongside their inhaled steroid were able to reduce their steroid dose by significantly more steps than children on the steroid alone. The average daily dose in the immunotherapy group dropped from about 330 micrograms to roughly 150 micrograms over two years, while the control group only decreased from about 290 to 205 micrograms.¹⁹ Immunotherapy is a slow process, typically requiring years of treatment, and it only works when a clear allergic trigger has been identified. But for the right patient, it offers a way to reduce steroid dependence by treating the upstream cause.

The SMART Approach as a Safety Net During Step-Down

One strategy that has gained traction for people stepping down their asthma medications is called SMART, short for Single Maintenance and Reliever Therapy. Instead of using a fixed daily maintenance inhaler plus a separate rescue inhaler (usually a short-acting bronchodilator), SMART uses a single combination inhaler containing a low-dose steroid and formoterol for both purposes. You take a low scheduled dose and use the same inhaler as your rescue when symptoms break through.²⁰

The advantage during a step-down is that SMART self-adjusts. On good days, you get only the low maintenance dose. On bad days, each rescue puff delivers a small extra dose of steroid right when your airways need it. This significantly reduces the risk of severe exacerbations compared with maintenance-only regimens that rely on a separate short-acting reliever.²⁰ For people who are nervous about reducing their steroid dose, SMART provides a built-in buffer: you are at a lower baseline dose most of the time, but you never go without steroid coverage entirely because your rescue inhaler contains one.

Inhaled Steroids During Pregnancy

Pregnant women with asthma face a particular dilemma. The impulse to minimize medication during pregnancy is understandable, but uncontrolled asthma itself poses real risks to both mother and baby, including preterm birth and low birth weight. A recent nationwide cohort study found that continuing inhaled steroids during the first trimester was not associated with increased risks of maternal or neonatal complications.²¹ Despite this reassuring evidence, the study also found that many women stop their inhaled steroids during early pregnancy on their own, presumably out of concern about the medication. The current guideline recommendation is to maintain your inhaled steroid during pregnancy rather than tapering, because the risk of an asthma flare-up during pregnancy is considered more dangerous than the medication itself. If you are planning to become pregnant and want to be on the lowest effective dose, the time to attempt a step-down is before conception, not after.

When Tapering Reveals a Different Kind of Asthma

An underappreciated aspect of steroid tapering is that it can serve as a diagnostic tool. Not all airway inflammation is the same. The type of inflammation most responsive to steroids is driven by a branch of the immune system sometimes labeled “T2-high.” A small but revealing randomized trial attempted to taper inhaled steroids specifically in patients whose asthma appeared to be “T2-low,” meaning their inflammation was not of the steroid-responsive type. Symptom scores in the tapering group stayed stable, and while certain biomarkers ticked upward, they remained in the low range. The researchers struggled to even find eligible patients: only 20 out of nearly 2,800 screened met the criteria, which underscores how few people with confirmed T2-low asthma are on inhaled steroids in the first place.

The practical implication: if you have been unable to get off inhaled steroids despite multiple attempts and good adherence, the inflammation driving your symptoms might be genuinely steroid-responsive, and you may need to stay on them. Conversely, if your doctor suspects your asthma is not driven by the typical inflammatory pathway, a careful taper with biomarker monitoring can help confirm that, and you may be able to come off steroids entirely because they were not doing much for you to begin with. The taper, in this case, is as much about understanding your disease as it is about reducing medication.

1
PubMed Central. Systemic effects of inhaled corticosteroids: an overview
2
PubMed. Potential adverse effects of the inhaled corticosteroids
3
The Annals of Family Medicine. Adverse Outcomes Associated With Inhaled Corticosteroid Use in Individuals With Chronic Obstructive Pulmonary Disease
4
Australian Prescriber. How to step down asthma preventer treatment in patients with well-controlled asthma – more is not always better
5
PubMed Central. Stepping Down Asthma Treatment: How and When
6
The Journal of Allergy and Clinical Immunology: In Practice. Step-Down Therapy for Asthma Well Controlled on Inhaled Corticosteroid and Long-Acting Beta-Agonist: A Randomized Clinical Trial
7
The Open Respiratory Medicine Journal. Inhaled Corticosteroids and Secondary Adrenal Insufficiency
8
PubMed Central. Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy
9
PubMed. Inhaled corticosteroids and HPA axis suppression: how important is it and how should it be managed?
10
npj Primary Care Respiratory Medicine. Rational use of inhaled corticosteroids for the treatment of COPD
11
PubMed Central. Inhaled corticosteroids in COPD: Benefits and risks
12
PubMed Central. Discontinuation Schedule of Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease
13
PubMed Central. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease
14
PubMed. Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD)
15
Respiratory Medicine. Exhaled nitric oxide to predict corticosteroid responsiveness and reduce asthma exacerbation rates
16
PubMed Central. Update on the Role of FeNO in Asthma Management
17
PubMed. Loss of control of asthma following inhaled corticosteroid withdrawal is associated with increased sputum interleukin-8 and neutrophils
18
The Lancet. Severe Asthma Can Be Controlled Without High-Dose Inhaled Steroids, Study Finds
19
The Journal of Allergy and Clinical Immunology. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial
20
The Journal of Allergy and Clinical Immunology: In Practice. A Practical Guide to Implementing SMART in Asthma Management
21
JAMA Network Open. Inhaled Corticosteroids Continuation in the First Trimester and Pregnancy Outcomes in Women With Asthma